67-30-1

Basic information

• Product Name: 3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID
• Synonyms: tetraiodothyroaceticacid;3,5-DIIODO-4-(4-HYDROXY-3,5-DIIODOPHENOXY)PHENYLACETIC ACID;4-[4-HYDROXY-3,5-DIIODOPHENOXY]-3,5-DIIODOBENZENEACETIC ACID;3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID;4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenylacetic acid;4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzeneacetic acid, Tetrac;[3,5-Diiodo-4-(3,5-diiodo-4-hydroxyphenoxy)phenyl]acetic acid;2-[3,5-Diiodo-4-(4-hydroxy-3,5-diiodophenoxy)phenyl]acetic acid
• CAS NO: 67-30-1
• Molecular Formula: C₁₄H₈I₄O₄
• Molecular Weight: 747.83
• EINECS: 200-649-1
• Product Categories: Aromatic Phenylacetic Acids and Derivatives;Aromatics;Drug Analogues;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 67-30-1.mol
• Article Data: 5

Chemical Properties

• Melting Point: 219-220 °C (decomp)
• Boiling Point: 544.8±50.0 °C(Predicted)
• Appearance: /
• Density: 2.727±0.06 g/cm3(Predicted)
• Storage Temp.: −20°C
• Solubility: acetone: soluble19.60 - 20.40mg/mL, clear, colorless (or faintly
• PKA: 3.98±0.10(Predicted)
• CAS DataBase Reference: 3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID(67-30-1)
• EPA Substance Registry System: 3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID(67-30-1)

Safety Data

• Hazard Codes: T+
• Statements: 28
• Safety Statements: 45
• RIDADR: UN 2811 6.1/PG 1
• WGK Germany: 3
• RTECS: CY1585800
• Hazardous Substances Data: 67-30-1(Hazardous Substances Data)

Usage

Uses

3,3′,5,5′-Tetraiodothyroacetic acid has been used: as a positive control to study the effects of ioxynil (IOX) diethylstilbestrol (DES) exposure on zebrafish embryosto study its effects on long-term potentiation (LTP) and long-term depression (LTD) in the dentate gyrus in urethane-anesthetized male ratsto determine its influence on the actions of thyroid-stimulating hormonethyroid-stimulating immunoglobulins in orbital fibroblast

Definition

ChEBI: A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'.

Biochem/physiol Actions

Studies in rats have reported that Tetrac may regulate TSH secretion under in vivo conditions1.

Upstream product

• 1155-40-4 2-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)acetic acid 
• 1083039-03-5 triisopropylsilyl 2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetate 
• 156-38-7 4-hydroxyphenylacetate 
• 92436-93-6 2-(3,5-diiodo-4-(4-methoxyphenoxy)phenyl)acetic acid 
• 861065-72-7 [4-(4-methoxy-phenoxy)-3,5-dinitro-phenyl]-acetic acid ethyl ester 
• 83799-60-4 (4-hydroxy-3,5-dinitro-phenyl)-acetic acid ethyl ester 
• 101588-11-8 C₁₇H₂₀N₂O₄ 
• 150-76-5 4-methoxy-phenol 
• 855937-68-7 [3,5-diiodo-4-(4-methoxy-phenoxy)-phenyl]-acetonitrile 
• 860687-73-6 1-(4-chloromethyl-2,6-diiodo-phenoxy)-4-methoxy-benzene 
• 85828-82-6 [3,5-diiodo-4-(4-methoxy-phenoxy)-phenyl]-acetic acid ethyl ester 

Downstream Products

• 1083039-03-5 triisopropylsilyl 2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetate 
• 1174546-73-6 N-cyclohexyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetamide 
• 1174546-71-4 tert-butyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl) acetate 
• 1300559-77-6 {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid 
• 1300857-63-9 C₁₈H₁₇I₄NO₄ 
• 1300559-73-2 lithium [4-(4-{2-[(diaminomethylene)amino]-ethoxy}-3,5-diiodophenoxy)-3,5-diiodophenyl]acetate 
• 1174546-78-1 triisopropylsilyl 2-(4-(3,5-diiodo-4-(oxiran-2-ylmethoxy)phenoxy)-3,5-diiodophenyl)acetate 
• 1174546-82-7 {4-[3,5-diiodo-4-(oxiran-2-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acidn 
• 1174546-76-9 N-cyclohexyl-2-(4-(3,5-diiodo-4-(oxiran-2-ylmethoxy)phenoxy)-3,5-diiodophenyl)acetamide 
• 1174546-80-5 oxiran-2-ylmethyl 2-(4-(3,5-diiodo-4-(oxiran-2-yl)methoxyphenoxy)-3,5-diiodophenyl)acetate 
• 1259014-89-5 2-(4-(4-(2-chloroethoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)-N-cyclohexylacetamide 

Relevant articles and documents

Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer

In the angiogenesis process, integrins, which are members of a family of cell surface transmembrane receptors, play a critical role particularly in blood vessel formation and the local release of vascular growth factors. Thyroid hormones such as L-thyroxine (T4) and 3,5,3′-triiodo-L-thyronine (T3) promote angiogenesis and tumor cell proliferation via integrin αvβ3 receptor. At or near an arginine-glycine-aspartate (RGD) recognition site on the binding pocket of integrin αvβ3, tetraiodothyroacetic acid (tetrac, a deaminated derivative of T4) is a thyrointegrin receptor antagonist and blocks the actions of T3 and T4 as well as different growth factors-mediated angiogenesis. In this study, we synthesized novel tetrac analogs by modifying the phenolic moiety of tetrac and tested them for their anti-angiogenesis activity using a Matrigel plug model for angiogenesis in mice. Pharmacological activity results showed that tetrac can accommodate numerous modifications and maintain its anti-angiogenesis activity.

COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS

A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and alphavbeta3 integrin antagonist in the same molecule

Note on the synthesis of the acetic acid analogue of thyroxine.

-